Recommendation ID
TA250/1
Question
Health-related quality of life studies comparing eribulin with vinorelbine and capecitabine should be conducted.
Any explanatory notes
(if applicable)
None.

Source guidance details

Comes from guidance
Eribulin for the treatment of locally advanced or metastatic breast cancer
Number
TA250
Date issued
April 2012

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No